Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Fernando Galanternik"'
Autor:
Ray Manneh Kopp, Fernando Galanternik, Fabio A. Schutz, Fabio Kater, Allan Ramos-Esquivel, Silvia Neciosup, Nora Sobrevilla-Moreno, Laura Bernal Vaca, Linda Ibatá-Bernal, Susan Martínez-Rojas, Maria T. Bourlon
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEUrothelial cancer accounts for approximately 3% of new cancer cases worldwide, with a high burden of disease in countries with medium and low human development indexes where its incidence and mortality are increasing. The purpose of this conse
Externí odkaz:
https://doaj.org/article/7ffb56e456bb4c76ba53c0a0038f4ea1
Autor:
Juan Bautista Blaquier, María José Bastianello, Martín Greco, Gonzalo Recondo (h), Gonzalo Recondo, Fernando Galanternik
Publikováno v:
Oncología Clínica. 25
En la recaída bioquímica posterior al tratamiento definitivo en cáncer de próstata, la localización anatómica y extensión de la enfermedad son fundamentales para definir el tratamiento. Métodos como tomografía computada (TC), centel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c42db487f798d9e05ad6ab31dc022ed
https://doi.org/10.56969/oc.v25i2.18
https://doi.org/10.56969/oc.v25i2.18
Autor:
Siamak Daneshmand, Renata Zaucha, Benjamin Adam Gartrell, Yair Lotan, Syed A. Hussain, Eugene K. Lee, Giuseppe Procopio, Fernando Galanternik, Vahid Naini, Jenna Carcione, Spyros Triantos, Mahadi Baig, Jodi K. Maranchie
Publikováno v:
Journal of Clinical Oncology. 41:504-504
504 Background: Current treatments (tx) of papillary NMIBC are not selective. Novel tx can be assessed on measurable disease (eg, a marker lesion) to rapidly and directly assess antitumor efficacy. FGFR inhibitor therapy may improve outcomes for pts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5d6bff537494a06ec6608086225bc96
https://doi.org/10.1200/jco.2023.41.6_suppl.504
https://doi.org/10.1200/jco.2023.41.6_suppl.504
Autor:
Fernando Galanternik, Gonzalo Recondo, Matías E. Valsecchi, Martín Greco, Máximo de la Vega, E. Diaz Cantón
Publikováno v:
Reviews on Recent Clinical Trials. 11:93-98
Colon cancer is a leading cause of cancer related mortality. Until very recently the only existing options that medical oncologists had to treat metastatic colon cancer were a combination of chemotherapy, anti-EGFR and anti-angiogenic agents. We curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bc04d865b7fdd807d141a59e6322a12
https://doi.org/10.2174/1574887111666160330121851
https://doi.org/10.2174/1574887111666160330121851
Autor:
Gonzalo Recondo, Fernando Galanternik, Martín Greco, Máximo de la Vega, E. Diaz Cantón, Matías E. Valsecchi
Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df5397d054a4f518db2304d6ef3fd65
http://www.eurekaselect.com/140784/article
http://www.eurekaselect.com/140784/article
